Friday, 19 Jul 2019

You are here

The RheumNow Week in Review – Modifiable Behavior (5.18.18)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis and modifiable behaviors that influence outcomes. 

  1. Osteoarthritis Initiative study of 1203 pts shows that running was not associated with worsening of knee pain or radiographic structural progression https://t.co/Y7UCTNMpKy
  2. Genentech announces that the FDA has approved Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis. https://t.co/E4z3K5LeBQ 
  3. RA pts have a greater risk of CVA; Study of 7904 RA pts shows that short-term (<7yrs) methotrexate might decrease ischemic stroke risk, but hydroxychloroquine and sulfasalazine did not. https://t.co/gRM9yrJOS0  RA 21% ^risk.
  4. Walmart (Sams) announced it is following CDC opioid prescribing recs and will soon limit initial opioid prescriptions to no more than seven days of supply, aiming avoid abuse https://t.co/uzn2xhbYL7
  5. UAB to lead the RECIPE trial in gout - a phase II trial to evaluate the utility of background mycophenolate (MMF) in patient receiving IV pegloticase injection for gout. Presumeably the MMF will block any interferring immunogenicity to PEG. https://t.co/ypBjwkeLpf
  6. Study of 148 SLE women shows obesity to be independently associated with worse disease activity, depressive symptoms, and symptoms of pain and fatigue. Obesity may be a modifiable target in SLE. https://t.co/XtrYr49msZ
  7. Lupus and diabetes have similar CVD risk; Claims data study of Medicaid pts shows SLE pts receive less lipids testing (66% less) & less likely to fill a statin Rx (82% less than DM; 11% less than Nl Pop) https://t.co/cjo4AtXHQs
  8. Opioid Marketing & Meals Tied to Opioid Prescribing  
  9. Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.